AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03368118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.
Study NCT00159952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intensive insulin therapy
Description: control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.~treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL
Study NCT02540122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 1
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
Study NCT02540122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 2
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
Study NCT02540122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 3
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
Study NCT02540122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 4
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
Study NCT02739659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: carbon-ion radiotherapy
Study NCT01888952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.
Study NCT01888952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
Study NCT02253888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV - Room condition
Study NCT02253888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV - Refrigerated conditions
Study NCT02984007 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information flyer
Description: Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the research assistant.
Study NCT02395731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND at Home-Plus Intervention
Description: MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
Study NCT02169570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study NCT02169570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT02169570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Study NCT02169570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vit D
Study NCT02169570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Calcium
Study NCT02169570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Calcium
Study NCT03905343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 600mg p.o. d1-21, q4w in combination with endocrine treatment for 3 years.
Study NCT03905343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mono-chemotherapy
Description: mono-chemotherapy for at least 12 weeks (afterwards, maintenance endocrine therapy ± ribociclib inhibitor is allowed) and up to 3 years.
Study NCT03905343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrine-Therapy
Description: The choice of endocrine therapy is up to the investigator, but the chosen endocrine therapy has to be registered to be used in combination with ribociclib in the investigated indication.
Study NCT00304759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 7800 cGy/39 fractions in 8 weeks
Description: see above
Study NCT00304759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6000 cGy/20 fractions in 4 weeks
Description: see above
Study NCT03560024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PACAP27
Description: PACAP27 is vasodilator of cerebral vessels
Study NCT03560024 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT02546297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort
Description: drug are used for 12 months
Study NCT02546297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva
Description: drug are used for 12 months
Study NCT00658905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhBSSL
Description: 0.15 g/L rhBSSL added to infant formula; one week treatment
Study NCT00658905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One week treatment
Study NCT04419922 — intervention group
Intervention type: BEHAVIORAL
Intervention: Smartphone Contingency Management Intervention
Description: Participants will provide baseline data on their recent substance use and smoking habits/severity. Participants will 1) download the DynamiCare Rewards app, and 2) receive a Carbon Monoxide breath testing device (iCO™ Smokerlyzer®) and reloadable debit card for receiving financial incentives. Participants will follow instructions on the app to take breath tests and receive incentives if the carbon monoxide breath result is less than 6 ppm (Cessation mode) or lower than 3 of the last 4 tests (Shaping mode). The app will use GPS to track if patients have attended their scheduled BrightView appointments (GPS is not used at any other time) and reward them for all kept appointments. The participant will also be able to view Cognitive Behavioral Therapy (CBT) modules on the app and receive incentives upon completing each module. At all times, the participant retains the right to choose whether to use and when to use the app, device, and funds for a total period of 4 months.
Study NCT01250509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craving and Lifestyle Management through Mindfulness
Description: A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
Study NCT01843725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: escalation dose of capecitabine continuously
Study NCT01843725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Intravenous 6mg/kg every 3 weeks
Study NCT01843725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
Study NCT01070446 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1
Description: This is a prospective, repeated measures study involving children with Cystic Fibrosis. Children will be assessed (1) before starting the choline supplement, (2) after taking the supplement for 6 months and after the supplement has been discontinued for 3 months.
Study NCT02253888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Study NCT02736708 — intervention group
Intervention type: DEVICE
Intervention: probe based confocal laser endomicroscopy
Description: real-time, microscopic imaging of tissue at the cellular level via a small diameter probe.
Study NCT00482170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enbrel (etanercept)
Description: Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
Study NCT00482170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Arm 2 = Enbrel 50 mg Autoinjector twice weekly
Study NCT00271219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: daily oral dosing 20-140 mg
Study NCT00271219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: sl daily 2-32 mg
Study NCT02025270 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem Cells
Description: 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
Study NCT01083992 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Galvus (vitagliptin)
Description: Galvus (vitagliptin)
Study NCT01083992 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Galvus + vitamin D
Description: Galvus + vitamin D
Study NCT04598308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: absolute flow and resistance measurements
Description: This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis~Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement.~Intention to measure Q and Rmicro are mandatory to be included in this registry.~Use of drugs either during or after the procedure should also exactly identical to normal routine.
Study NCT01509001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 750 to 2500 mg/day, two times a day during 4 months
Study NCT01509001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1 to 8 mg/day , two times a dya, during 4 months.
Study NCT03745898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Active nocturnal oxygen concentrator
Study NCT03745898 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Room Air
Description: Sham nocturnal oxygen concentrator (room air)
Study NCT02807883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
Study NCT02807883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Hematopoietic progenitor cell infusion
Study NCT02142153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile
Study NCT02142153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
Study NCT00022737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT and IV
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine tablet
Description: Given orally
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT, IV, and orally
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM
Study NCT00022737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00022737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
Study NCT00022737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
Study NCT00022737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
Study NCT00022737 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT04744753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Ionophore A23187
Description: Calcium Ionophore A23187 is used in laboratories to increase intracellular Ca2+ levels in intact cells. It also uncouples oxidative phosphorylation, the process cells use to synthesize Adenosine triphosphate which they use for energy. In addition, A23187 inhibits mitochondrial ATPase activity. A23187 also induces apoptosis in some cells (e.g. mouse lymphoma cell line, or S49, and Jurkat cells) and prevents it in others (e.g. cells dependent on interleukin 3 that have had the factor withdrawn).~In IVF field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with Globozoospermia (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF.
Study NCT04050085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04050085 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04050085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR9 Agonist SD-101
Description: Given intratumorally
Study NCT03953599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-STAR-T cells
Description: CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
Study NCT03363139 — intervention group
Intervention type: DRUG
Intervention: Tirosin Kinase Inhibitors
Description: Patients that received Tyrosin Kinase inhibitors and progressed
Study NCT04796077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pop-Up Book
Description: Patients spent 5-10 minutes reading an illustrated pop-up book that promoted active learning about the process of general anesthesia induction.
Study NCT04531020 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PAED measurement
Description: The incidence of emergence delirium, defined as PAED score above 10 points minimally in one of the PAED score measurements. PAED score will be measured in 0., 5., 10., 15., and 20. minute after PACU admission.
Study NCT02908763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa
Description: peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
Study NCT03462004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPIV3/ΔHNF/EbovZ GP vaccine
Description: Administered intranasally
Study NCT03462004 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intranasally
Study NCT05570604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweep Seeker
Description: The person is asked to clear the rows of blocks presented on the screen, either by moving them into horizontal or vertical blocks that have identical color. The goal is to refine and increase the response of primary visual cortex neurons and to enable the person to increase speed and accuracy of visual processing (executive function) and visual memory.
Study NCT05570604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bird Safari
Description: The user is first presented with a target bird. Subsequently, a group of birds is presented in the peripheral vision and then disappears when the trial begins. The user selects the section of the screen where the target bird appeared. The presentation speed adapts with user performance (i.e. better performance = faster presentation). The goal is to improve speed and accuracy of object identification in peripheral vision and improve visual precision important for improving memory.
Study NCT05570604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jewel Diver
Description: The person is first presented objects (jewels) on the screen. The objects are then covered with occluders (bubbles) and then identical distracters are presented. The objects move around in screen and when the movement stops, the user chooses the occluders that cover the jewels. The number of jewels adapts to performance (more jewels = better performance). The goal is to improve divided visual attention, sustained visual attention, visual working memory, and visual precision.
Study NCT05570604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Master Gardener
Description: The person is presented a series of target stimuli and distracters which are presented at one time and then disappear. The locations of the stimuli are marked by icons, and the user chooses the icons where the target stimuli were once located. The goal is to increase speed and accuracy as well as the ability to extract information accurately.
Study NCT05570604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Road Tour
Description: The person is presented with a target vehicle briefly in both the center of the screen and in one of eight locations in the periphery. Two vehicles are then presented briefly in the center of the screen, one of which is the target vehicle. The user must identify the location of the target vehicle in the periphery as well as identify which was the target vehicle that appeared in the center. The goal of this activity is to improve divided attention and ability to extract information and discard irrelevant information from peripheral vision.
Study NCT05570604 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized Crossword Puzzles
Description: The program offers a pre-determined set of computerized crossword puzzles. The site has over 100,000 puzzles and can be accessed easily via the web and are free to users. The computerized crossword puzzles do not provide for progressive challenges of increasing speed, visual field size, number of distractors or degree of difficulty of targeted stimulus differentiation.
Study NCT02661191 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral cholecalciferol
Description: Inhaled corticosteroids and long-acting beta-agonists, salbutamol
Study NCT00778349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin solution 100 mg/mL
Study NCT03131687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirzepatide
Description: Administered SC
Study NCT03131687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC